The objective of this study was to elucidate the molecular characteristics of a Chinese family with Glanzmann’s thrombasthenia (GT). The proband was diagnosed with GT based on clinical manifestations, platelet aggregation, and the expression of CD41 and CD61 in platelets. Whole-exome and Sanger sequencing were used to detect genetic defects related to GT in the proband and the family of the pedigree. Whole-exome sequencing showed a c.1784–1802delinsGTCACA, p. S595Cfs*70 homozygous mutation in exon 11 of the ITGB3 gene in the proband. Heterozygous mutations were found in the proband’s parents, grandmother, uncle, aunt, and younger brother. This novel p. S595Cfs*70 ITGB3 gene mutation is not present in the 1000 Genomes and ExAC databases.

1.
Glanzmann
E
.
Hereditäre hämorrhagische Thrombasthenie. Ein Beitrag zur Pathologie der Blutplättchen
.
Jb Kinderheilkd
.
1918
;
88
:
113
41
.
2.
Toogeh
G
,
Sharifian
R
,
Lak
M
,
Safaee
R
,
Artoni
A
,
Peyvandi
F
.
Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran
.
Am J Hematol
.
2004 Oct
;
77
(
2
):
198
9
. .
3.
Newman
PJ
,
Seligsohn
U
,
Lyman
S
,
Coller
BS
.
The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel
.
Proc Natl Acad Sci U S A
.
1991 Apr
;
88
(
8
):
3160
4
. .
4.
Mansour
W
,
Einav
Y
,
Hauschner
H
,
Koren
A
,
Seligsohn
U
,
Rosenberg
N
.
An αIIb mutation in patients with Glanzmann thrombasthenia located in the N-terminus of blade 1 of the β-propeller (Asn2Asp) disrupts a calcium binding site in blade 6
.
J Thromb Hemost
.
2011 Jan
;
9
(
1
):
192
200
.
5.
Nurden
AT
,
Pillois
X
,
Fiore
M
,
Alessi
MC
,
Bonduel
M
,
Dreyfus
M
,
Expanding the mutation spectrum affecting alphaIIbbeta3 integrin in Glanzmann thrombasthenia: screening of the ITGA2B and ITGB3 genes in a large international cohort
.
Hum Mutat
.
2015 May
;
36
(
5
):
548
61
.
6.
Hauschner
H
,
Landau
M
,
Seligsohn
U
,
Rosenberg
N
.
A unique interaction between alphaIIb and beta3 in the head region is essential for outside-in signaling-related functions of alphaIIbbeta3 integrin
.
Blood
.
2010 Jun
;
115
(
22
):
4542
50
. .
7.
Xiong
JP
,
Mahalingham
B
,
Alonso
JL
,
Borrelli
LA
,
Rui
X
,
Anand
S
,
Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha/beta transmembrane fragment
.
J Cell Biol
.
2009 Aug
;
186
(
4
):
589
600
. .
8.
Di Minno
G
,
Coppola
A
,
Di Minno
MN
,
Poon
MC
.
Glanzmann’s thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues
.
Thromb Hemost
.
2009 Dec
;
102
(
6
):
1157
64
. .
9.
Zafarghandi Motlagh
F
,
Fallah
MS
,
Bagherian
H
,
Shirzadeh
T
,
Ghasri
S
,
Dabbagh
S
,
Molecular genetic diagnosis of Glanzmann syndrome in Iranian population; reporting novel and recurrent mutations
.
Orphanet J Rare Dis
.
2019 Apr
;
14
(
1
):
87
. .
10.
Solh
T
,
Botsford
A
,
Solh
M
.
Glanzmann’s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options
.
J Blood Med
.
2015
;
6
:
219
27
. .
11.
Nurden
AT
.
Glanzmann thrombasthenia
.
Orphanet J Rare Dis
.
2006 Apr
;
1
:
10
. .
12.
Shattil
SJ
,
Kashiwagi
H
,
Pampori
N
.
Integrin signaling: the platelet paradigm
.
Blood
.
1998 Apr
;
91
(
8
):
2645
57
. .
13.
George
JN
,
Caen
JP
,
Nurden
AT
.
Glanzmann’s thrombasthenia: the spectrum of clinical disease
.
Blood
.
1990 Apr
;
75
(
7
):
1383
95
. .
14.
Nurden
AT
,
Pillois
X
,
Nurden
P
.
Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment
.
Expert Rev Hematol
.
2012 Oct
;
5
(
5
):
487
503
. .
15.
Kannan
M
,
Ahmad
F
,
Yadav
BK
,
Kumar
R
,
Choudhry
VP
,
Saxena
R
.
Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann thrombasthenia
.
J Thromb Hemost
.
2009 Nov
;
7
(
11
):
1878
85
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.